Sudoxicam (1-10 mg/kg; oral administration; daily; for 7 days; rats) treatment effective reduces plasma inflammation units, reduces the swelling of inflamed hind-paws and restores toward normal the daily gain in body weight[2].
In the intact rat, Sudoxicam significantly inhibited edema formation at doses as low as 0.1 mg/kg, p.o[2].
Sudoxicam inhibits the erythema caused by ultraviolet irradiation in the guinea pig.
Sudoxicam (3.3 mg/kg, i.p.) is capable of counteracting the pyrexia induced by the intraperitoneal injection of typhoid/paratyphoid vaccine in rats, maintaining body temperature about that of uninjected control rats[2].
The plasma half-life of Sudoxicam ranged between 8 hours (monkey), 13 hours (rat), and 60 hours (dog)[2].
| Animal Model: | Rats injected with ,i>M. butyrieum[2] |
| Dosage: | 1 mg/kg, 3.3 mg/kg, 10 mg/kg |
| Administration: | Oral administration; daily; for 7 days |
| Result: | Were both effective in reducing plasma inflammation units, in reducing the swelling of inflamed hind-paws.
|
